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Treatment as prevention (TasP) refers to the use of antiretroviral therapy to reduce HIV 
viremia to ‘undetectable’ levels which in turn eliminates the risk of HIV transmission. 
Significant efforts have been made to increase awareness and understanding of TasP in many 
countries but not in the Eastern Mediterranean Region (EMR) where HIV remains a highly 
stigmatized condition especially in men who have sex with men. In this editorial, we discuss 
the effectiveness of TasP and public understanding of it, with a focus on men who have sex 
with men living in the EMR. We argue that increasing awareness and understanding of TasP 
could enable the concentrated epidemic in men who have sex with men in the EMR to move 







The significant reduction in HIV viremia to ‘undetectable’ levels (HIV plasma viral 
load below 40 copies/ml) in response to effective antiretroviral therapy (ART) removes the 
risk of HIV transmission [1]. This approach, known as ‘treatment as prevention’ (TasP), has 
proven to be successful especially in men who have sex with men (MSM) and in other key 
populations. In view of the demonstrable effectiveness of TasP, significant efforts have been 
made to increase public awareness and understanding of this approach in Western, 
industrialized societies like the US and the UK. However, this has not been the case in the 
Eastern Mediterranean Region (EMR)1, in which HIV remains a highly stigmatized 
condition, which is seldom discussed mainly because of its association with MSM – a 
stigmatized group in EMR society. In this editorial, we discuss the effectiveness of TasP in 
major observational studies and current levels of public understanding of, and belief in, TasP, 
with a focus on MSM in the EMR. We argue that increasing awareness and understanding of 
TasP in MSM in the EMR could enable the epidemic to move closer towards the UNAIDS 
target of 90-90-902.  
 
TasP: Science & Public Understanding 
The notion of TasP in MSM has received significant empirical support in major 
observational studies [1-4]. The HIV Prevention Trials Network (HPTN) 052 study led to the 
landmark finding that no HIV transmission from the HIV-positive to the HIV-negative 
primary partner in serodiscordant couples having condomless sex when the HIV-positive 
partner had a stable suppressed plasma viral load (‘suppression’ defined by HIV viremia 
levels < 200 copies/ml) [2]. Moreover, the PARTNER study of 1166 serodiscordant 
                                                 
1 EMR according to WHO includes Afghanistan, Bahrain, Djibouti, Egypt, Iran, Iraq, Jordan, Kuwait, Lebanon, 
Libya, Morocco, Oman, Pakistan, Qatar, Saudi Arabia, Somalia, Sudan, Syrian Arab Republic, Tunisia, United 
Arab Emirates and Yemen. 
2 The UNAIDS "90-90-90" strategy calls for 90% of HIV-infected individuals to be diagnosed by 2020, 90% of 
whom will be on anti-retroviral therapy (ART) and 90% of whom will achieve sustained virologic suppression. 
Reaching these targets by 2020 will reduce the HIV epidemic to a low-level endemic disease by 2030. 
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heterosexual and gay male couples yielded no evidence of any HIV transmissions in the same 
context [3]. Most recently, data from the Opposites Attract study (358 serodiscordant male 
couples with high rates of condomless anal sex) revealed no HIV transmissions [4]. These 
large studies have collectively contributed to the evidence base that people living with HIV 
(PLHIV) with an undetectable viral load (‘undetectable’ defined by HIV viremia levels < 40 
copies/ml) cannot transmit HIV sexually. 
Consequently, the notion of TasP has been supported by many health agencies, health 
departments and HIV community advocates [5]. In July 2018, the World Health Organization 
(WHO) declared that “[The mentioned above] data have led to an increasing consensus that 
people who have achieved and maintained undetectable viral load cannot transmit HIV 
sexually to their partners” [6].  
Yet, despite this consensus in the scientific community, MSM vary in their levels of 
understanding and acceptance of TasP. This was demonstrated in a study from Canada (719 
MSM) where only 46% heard of TasP with differences by HIV status (69% HIV-positive vs. 
41% HIV-negative (p<0.0001)) [7]. In this report, only 6% of HIV-negative men believed in 
TasP. In Australia, 13.1% of MSM surveyed in 2015 believed in TasP [8]. In the UK, a report 
showed that even MSM living with HIV were ambivalent about the effectiveness of TasP and 
expressed fears of onward transmission [9]. A large survey of 12,222 MSM in the US showed 
that a high level of HIV knowledge and low HIV stigma was associated with greater 
awareness of TasP among HIV-negative people [10]. 
 
HIV in the EMR  
According to the WHO, new HIV infections are on the rise in the EMR. The 
estimated number of new infections increased by 28% over the past 7 years to reach 36,000 
in 2017. This figure represents the highest regional incidence rate [11].  
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While the percentage of the general adult population living with HIV in the Region 
remained among the lowest globally (<0.1%), key populations continue to be 
disproportionately affected. Ninety-five percent of new HIV infections in the Region are 
within key populations, i.e. people who inject drugs, MSM and sex workers [12].  Limited 
access to HIV testing for PLHIV remains the biggest obstacle to the delivery of life-saving 
antiretroviral therapy in the EMR where only 34% of PLHIV are aware of their infection 
[11]. In addition, sexual and injecting partners of PLHIV are at high risk of HIV infection. 
Extending HIV testing to these population groups would help identify PLHIV who, 
otherwise, would not know their HIV status [12]. In spite of this, countries of the EMR 
reported a negligible number of partners of PLHIV who received an HIV test in 2017 [13]. 
Thus, low testing rates cast doubt on the accuracy of current epidemiological data on the HIV 
epidemic in the EMR.   
Unlike many Western industrialized countries which have achieved, or are close to 
achieving, 90-90-90 by the end of 2017, the EMR has the lowest performance of all WHO 
regions, falling short of the 2020 fast-track targets [11]. This can be attributed in part to 
stigma, discrimination and risk of criminalization, which reduces the reach and effectiveness 
of HIV prevention programs in the EMR.  Protracted humanitarian emergencies and 
population mobility in many countries of the Region pose an additional challenge for HIV 
prevention.  
 
Can TasP get us closer to 90-90-90 in the EMR? 
In light of these data, promoting public understanding of TasP (that is, the message of 
“undetectable=untransmittable”) is critical in the EMR, especially in key populations. 
Awareness and understanding of TasP may lead to: (1) a reduction in HIV stigma; (2) less 
fear of testing positive and, thus, increased HIV testing; (3) a greater willingness to disclose 
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one’s HIV status to significant others; (4) and to a better mental health [12]. For instance, in 
the UK new HIV infections in London have fallen by more than 40% in recent years and 
London has already reached 95–98–97 of the global targets [14]. These rates could be 
achieved with a combination of (1) increasing regular testing in high-risk MSM to facilitate 
early diagnosis, and (2) early reducing the community viral load through the offer of 
immediate initiation of antiretroviral treatment [15]. 
The full potential of TasP in the EMR cannot be exploited if HIV testing for PLHIV 
remains low (only 34% of PLHIV are aware of their infection) and if ART coverage is 15% 
[11]. The scarce behavioral studies from the EMR in key populations, including MSM, 
evidence of low HIV testing rates, high levels of condomless anal sex, among many other 
political, religious and social challenges remain obstacles to achieving 90-90-90 [16].  
First, a significant challenge is stigma and discrimination due to the fact that same-sex 
conduct is illegal in many EMR countries. Homosexuality is punishable by imprisonment, 
and MSM may experience generalized social stigma and discrimination in society [13]. 
Second, MSM may experience stigma in from healthcare services which constitutes a barrier 
in accessing healthcare services and HIV testing [13]. Third, due to stigma, denial and 
political factors, several EMR governments still assume that HIV is not a significant public 
health issue in their societies and thus do not dedicate resources to curbing it, instead 
prioritizing other diseases [13]. This silencing of HIV has led to delayed action to curb the 
epidemic, allowing HIV incidence to increase and for its syndemics to thrive.  
Against this social, political and policy backdrop, it seems unlikely that UNAIDS 
targets in the EMR will get much closer 90-90-90, unless a bold policy stance on HIV is 
taken and TasP, as a key prevention method, is embraced. This will require a widespread 
campaign to raise awareness of the importance of regular and consistent HIV testing in 
people at risk of HIV and a parallel campaign to educate people about TasP and its role 
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within the whole HIV cascade [17]. For TasP to be successful in this area of the world, key 
stakeholders will need to be convinced of its clinical effectiveness in improving HIV 
prevention and prognosis, and of its long-term cost effectiveness [17]. 
Countries that responded pragmatically to the HIV epidemic early on were able to 
control the spread of infection. The EMR, as a relatively low prevalence region, still has a 
window of opportunity for curbing its HIV epidemic. HIV testing, ART initiation, and viral 
load monitoring are needed, together with combination HIV prevention. Ensuring access to 
available prevention options, and facilitating awareness and understanding of TasP, will not 
only prevent HIV transmission but also contribute to much needed stigma reduction. This 
will undoubtedly allow people – both HIV-negative and HIV-positive - to have more open 
discussions about their sexual health and ultimately to make more informed decisions about 
their sexual lives.  
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